Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777176 · ClinicalTrials.gov registry record · Phase 3
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
A Phase 3 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT03777176 is a Phase 3 study that has completed, run by Zealand Pharma. The registered enrollment target is 32 participants.
The verdict
NCT03777176, a Phase 3 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
Interventions
- OTHER Standard of Care
- DRUG Dasiglucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03777176
The ClinicalTrials.gov registry entry for NCT03777176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03777176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03777176 about?
NCT03777176 is a clinical study titled "A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism". The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
What is the current status of trial NCT03777176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2019-02-07. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03777176?
The interventions under investigation include: Standard of Care (OTHER), Dasiglucagon (DRUG).
Who is sponsoring clinical trial NCT03777176?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.